Refractive and Biometric Outcomes in Patients with Retinopathy of Prematurity Treated with Intravitreal Injection of Ranibizumab as Compared with Bevacizumab: A Clinical Study of Correction at Three Years of Age

Table 4

Refractive errors and biometry in patients treated with ranibizumab or bevacizumab.

	Ranibizumab ()		Bevacizumab ()
	Mean ± SD	Median (95% CI)	Mean ± SD	Median (95% CI)
SE (diopters)	−0.12 ± 1.12	+0.13 (−0.36 to +0.38)	−0.65 ± 3.83	+0.38 (−0.17 to +1.09)	0.19
Cylinder (diopters)	−1.18 ± 0.89	−1.00 (−1.30 to −0.75)	−1.60 ± 1.80	−1.00 (−1.59 to −0.75)	0.55
Axial length (mm)	21.90 ± 0.94	22.33 (21.39 to 22.56)	21.90 ± 1.27	21.67 (21.31 to 21.95)	0.22
Cornea radius (mm)	7.64 ± 0.26	7.76 (7.45 to 7.83)	7.60 ± 0.22	7.60 (7.52 to 7.68)	0.35
ACD (mm)	3.53 ± 0.22	3.51 (3.35 to 3.74)	3.33 ± 0.23	3.37 (3.22 to 3.44)	0.01
Lens thickness (mm)	3.82 ± 0.15	3.78 (3.74 to 3.98)	3.85 ± 0.20	3.82 (3.78 to 3.94)	0.60

ACD: anterior chamber depth; SE: spherical equivalent; Mann–Whitney U test.